FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.
Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...
PsyPost on MSN1d
Fascinating study links depression symptoms to effort-based decision-making patternsA new study published in Psychological Medicine sheds light on how specific depression symptoms are related to decisions ...
The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...
A non-invasive form of treatment for clinical depression is hoping to provide even faster results thanks to new research.
GlobalData on MSN4d
J&J’s Spravato receives FDA label expansion for depression monotherapyJohnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...
Biochemical analyses provide an answer to the question of how the gut bacterium Morganella morganii might contribute to some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback